ZNF397 Antibody

What applications have ZNF397 antibodies been validated for in research settings?

ZNF397 antibodies have been validated for multiple research applications, with varying success rates depending on the specific antibody clone and source. The most commonly validated applications include:

Most commercially available ZNF397 antibodies demonstrate strongest reactivity in Western blot applications, with polyclonal rabbit antibodies showing the broadest application spectrum . The monoclonal antibody PCRP-ZNF397-2F6 (mouse IgG2a) has been specifically characterized for immunoprecipitation and microarray applications by the NIH Protein Capture Reagents Program .

For optimal results in Western blot applications, samples from PC-3 cells and mouse testis tissue have demonstrated positive detection with several antibody clones .

What is the molecular profile of ZNF397 and how does this impact antibody selection?

ZNF397 (also known as ZNF47 or ZSCAN15) is a complex zinc finger protein with the following characteristics that impact antibody selection:

When selecting antibodies, researchers should consider which protein domains are targeted by the antibody epitope. For instance, antibodies recognizing the SCAN domain (aa 41-136) have been developed specifically for functional studies, as this domain is critical for protein-protein interactions and DNA binding inhibition of TET2 .

The calculated molecular weight is approximately 61 kDa, but observed weights between 60-63 kDa are common on Western blots .

How does ZNF397 deficiency contribute to AR-targeted therapy resistance in prostate cancer, and how can antibodies help investigate this mechanism?

ZNF397 deficiency has been identified as a key driver of resistance to AR-targeted therapies in prostate cancer through multiple mechanisms:

• AR Signaling Impairment: ZNF397 knockout (KO) leads to profound loss of AR binding to canonical target genes (more than 40% reduction), comparable to the impact seen with the loss of the known AR coactivator FOXA1 .

• TET2-Driven Epigenetic Rewiring: In ZNF397-deficient cells, TET2 (ten-eleven translocation methylcytosine dioxygenase 2) binding is significantly upregulated at genomic loci, driving epigenetic changes .

• Lineage Plasticity: ZNF397 loss triggers a shift from AR-driven, therapy-sensitive prostate cancer to TET2-driven, lineage plastic, therapy-resistant cancer .

For investigating these mechanisms, researchers can employ ZNF397 antibodies in the following experimental designs:

The research findings suggest that ZNF397 functions as a molecular switch, and its status strongly correlates with progression-free survival in metastatic castration-resistant prostate cancer (mCRPC) patients undergoing AR-targeted therapies .

What are the best practices for optimizing ZNF397 antibody use in chromatin immunoprecipitation (ChIP) studies?

Optimizing ZNF397 antibodies for ChIP studies requires special considerations due to the protein's nuclear localization and DNA-binding properties:

• Crosslinking Optimization:

  • Use dual crosslinking with 1.5 mM EGS (ethylene glycol bis[succinimidylsuccinate]) for 30 minutes followed by 1% formaldehyde for 10 minutes

  • This approach has been successfully used to detect ZNF397 binding to AR target genes

• Sonication Parameters:

  • Chromatin should be sheared to 200-500 bp fragments

  • Use of Bioruptor or similar devices with cycles of 30 seconds on/30 seconds off for 30-45 cycles

• Antibody Selection and Validation:

  • Monoclonal antibodies generally provide more consistent results for ChIP

  • Validate antibody specificity using ZNF397-KO cells as negative controls

  • The epitope targeting the SCAN domain (aa 41-136) has shown efficacy in detecting ZNF397-DNA interactions

• Controls and Normalization:

  • Include IgG control and input samples

  • Use canonical ZNF397 binding sites as positive controls

  • Normalize to non-target regions

• Downstream Analysis:

  • For ZNF397/AR co-binding studies, parallel ChIP for both proteins is recommended

  • Sequential ChIP (ChIP-reChIP) can be used to identify genomic loci where ZNF397 and AR co-occupy

In published research, ChIP-qPCR has successfully demonstrated that ZNF397-KO largely abolishes AR binding to canonical target genes, highlighting the importance of ZNF397 as an AR coactivator .

How can researchers distinguish between different ZNF397 isoforms, and what are the methodological considerations?

ZNF397 exists in multiple isoforms with distinct functions, making isoform-specific detection critical for understanding its role in cancer progression:

For isoform-specific detection:

• Western Blot Optimization:

  • Use gradient gels (4-15%) to effectively separate isoforms with small molecular weight differences

  • Extended run times (>2 hours) at lower voltage (80V) improve separation

  • Include positive controls for each isoform when available

• RT-qPCR Approach:

  • Design primers spanning unique exon junctions for each isoform

  • Validate primer specificity using synthetic templates or overexpression constructs

  • Use absolute quantification with isoform-specific standards

• Immunoprecipitation Strategy:

  • Use antibodies targeting common regions to pull down all isoforms

  • Follow with isoform-specific western blotting or mass spectrometry

  • Include isoform-specific blocking peptides to validate specificity

Isoform 3 is of particular interest as it has been documented to act as a DNA-dependent transcriptional repressor, while isoforms 1 and 3 can both homo- and hetero-associate . Research has shown that homo-association of isoform 1 is dependent on the presence of the SCAN domain, highlighting the functional importance of this domain in protein interactions .

What is the correlation between ZNF397 expression and clinical outcomes in cancer patients, and how can this be investigated?

Research has established significant correlations between ZNF397 expression and clinical outcomes in cancer patients, particularly in prostate cancer:

For investigating these correlations, researchers can employ the following methodological approaches:

When designing such studies, researchers should:

• Use validated antibodies with demonstrated specificity in IHC applications

• Include appropriate positive controls (testis tissue shows strong expression) and negative controls

• Consider dual staining with AR to evaluate the ZNF397-AR relationship in clinical samples

• Correlate with genomic data on ZNF397 mutations or deletions when available

In the SU2C metastatic CRPC cohort, dividing patients based on ZNF397 expression (above or below median) revealed that patients with low expression developed AR-targeted therapy resistance significantly faster than those with high expression, highlighting its potential as a biomarker .

How does the ZNF397-TET2 interaction influence cancer epigenetics, and what methods can be used to study this relationship?

The ZNF397-TET2 interaction represents a critical epigenetic switch in cancer progression:

• Mechanism of Interaction:

  • The SCAN domain of ZNF397 blocks the DNA binding of the TET2 catalytic domain

  • ZNF397 functions as a barrier to TET2 DNA binding and activity

  • ZNF397 deficiency leads to increased TET2 binding at genomic loci

• Functional Consequences:

  • Increased TET2 activity promotes DNA demethylation and epigenetic rewiring

  • This rewiring drives lineage plasticity and therapy resistance

  • TET2 knockout can reverse the effects of ZNF397 loss on lineage marker expression

To study this relationship, researchers can employ these methodological approaches:

Key experimental designs should include:

• Domain Mapping:

  • Generate ZNF397 constructs with mutations or deletions in the SCAN domain

  • Assess their ability to inhibit TET2 activity in vitro and in cells

  • Measure downstream effects on lineage markers and therapy resistance

• Epigenetic Profiling:

  • Compare DNA methylation and hydroxymethylation patterns in control vs ZNF397-KO cells

  • Correlate with changes in gene expression and chromatin accessibility

  • Focus on regions showing differential TET2 binding

• Rescue Experiments:

  • Reintroduce the SCAN domain of ZNF397 in ZNF397-KO cells

  • Assess whether this restores AR signaling and therapy sensitivity

  • Research has shown that resistance conferred by ZNF397-KO can be fully rescued by reintroduction of the SCAN domain

This interaction represents a promising therapeutic target, as research suggests that targeting TET2 and epigenetic rewiring could potentially overcome therapy resistance in patients with ZNF397-deficient tumors .

What are the optimal tissue preparation protocols for ZNF397 immunohistochemistry?

Achieving optimal ZNF397 detection in tissue samples requires careful consideration of fixation, antigen retrieval, and staining protocols:

Specific considerations for ZNF397 IHC:

• Positive Control Selection:

  • Mouse liver tissue has been validated as a positive control

  • Testis tissue shows strong expression and can serve as an alternative control

• Signal Localization and Interpretation:

  • ZNF397 shows primarily nuclear staining, with potential centromere localization during specific cell cycle phases

  • Digital image analysis can help quantify nuclear signal intensity

  • Consider dual staining with AR for correlation studies in prostate cancer

• Troubleshooting Weak Signals:

  • Extend antigen retrieval time to 30 minutes

  • Use signal amplification systems such as tyramide signal amplification

  • Try multiple antibodies targeting different epitopes

These protocols have been successfully implemented in studies correlating ZNF397 expression with clinical outcomes in prostate cancer samples .

What are the recommended protocols for detecting ZNF397-AR interactions in cell and tissue samples?

Investigating the functional interaction between ZNF397 and AR requires specialized techniques to detect their physical association and co-localization:

• Co-Immunoprecipitation Protocols:

• Proximity Ligation Assay (PLA) Protocol:

  • Particularly valuable for detecting protein interactions in situ

  • Fixed cells or FFPE tissue sections can be used

  • Primary antibodies must be from different species (e.g., rabbit anti-ZNF397 and mouse anti-AR)

  • Provides spatial information about interaction sites within the nucleus

• Chromatin Immunoprecipitation (ChIP) Approaches:

  • Sequential ChIP (ChIP-reChIP) to identify genomic loci with co-occupancy

  • Parallel ChIP with bioinformatic overlap analysis

  • Published research has demonstrated that ZNF397 knockout significantly reduces AR binding to target genes

• FRET/BRET Analysis:

  • For live cell interaction studies

  • Requires fusion protein construction (e.g., ZNF397-CFP and AR-YFP)

  • Can reveal dynamic interaction changes upon ligand treatment

Research has established that ZNF397 functions as a bona fide coactivator of the androgen receptor, essential for the transcriptional program governing AR-driven luminal lineage . In mechanistic studies, ZNF397 knockout led to a profound loss of AR binding, comparable to the effect seen with the loss of known AR coactivator FOXA1 .

How can researchers effectively silence ZNF397 expression in experimental models to study its function?

Multiple approaches have been validated for silencing ZNF397 expression in experimental models, each with specific advantages:

For CRISPR/Cas9 knockout approaches:

• Guide RNA Selection:

  • Multiple independent guide RNAs have been validated in prostate cancer models

  • Target early exons for complete protein disruption

  • Verify knockout by Western blot and genomic sequencing

• Phenotypic Validation:

  • Assess AR signaling through qRT-PCR of canonical targets

  • Measure resistance to enzalutamide using viability assays

  • Research has shown ZNF397-KO confers resistance to multiple AR antagonists, including enzalutamide, apalutamide, and darolutamide

For inducible systems:

• Doxycycline-Inducible shRNA System:

  • Allows temporal control of ZNF397 knockdown

  • Studies have demonstrated that ZNF397-KD conferred enzalutamide resistance was both rapid and reversible

  • Useful for studying dynamic processes without cellular adaptation

• In Vivo Applications:

  • ZNF397-KO in LNCaP/AR xenografts showed complete resistance to enzalutamide in castrated mice

  • CWR22Pc xenografts with ZNF397-KO exhibited significantly higher resistance to AR-targeted therapies

These genetic approaches have revealed that ZNF397 deficiency triggers a profound shift in cellular phenotype, moving from AR-dependent to AR-independent states, with significant implications for therapy resistance .

What are the critical controls needed when studying ZNF397 in relation to AR signaling and TET2 activity?

Robust experimental design requires careful consideration of controls to validate findings related to ZNF397 function:

For mechanistic studies of ZNF397-TET2 interaction:

• Domain-Specific Controls:

  • SCAN domain mutations that specifically disrupt TET2 interaction

  • TET2 truncations to map interaction regions

  • Competition assays with purified SCAN domain protein

• Pharmacological Approaches:

  • TET inhibitors to phenocopy TET2 knockout effects

  • AR signaling modulators (agonists/antagonists) to assess pathway sensitivity

  • Epigenetic modifiers to alter DNA methylation status

• Lineage Plasticity Markers:

  • Track expression of basal, EMT-like, stem-like and NE-like markers

  • Research has shown TET2 knockout largely reverses the upregulation of these markers in ZNF397-deficient cells

In xenograft models, researchers have successfully demonstrated that ZNF397-KO tumors have substantially increased Ki67 signal compared to control tumors, indicating that ZNF397 loss protects prostate cancer tumors from therapy-induced inhibition of proliferation . These findings were validated using appropriate experimental controls, including wild-type xenografts treated with the same therapy regimens.

How can ZNF397 antibodies be employed in developing potential biomarkers for therapy resistance in prostate cancer?

The strong correlation between ZNF397 expression and therapy resistance makes it a promising biomarker candidate:

• Clinical Assay Development:

  • Immunohistochemistry-based scoring systems calibrated to predict therapy response

  • Digital pathology algorithms for quantitative ZNF397 nuclear expression

  • Combined ZNF397/AR/TET2 panels for improved predictive power

• Liquid Biopsy Approaches:

  • Detection of circulating tumor cells with ZNF397 expression profiling

  • Cell-free DNA methylation analysis of ZNF397 regulatory regions

  • Correlation with circulating tumor DNA AR alterations

• Companion Diagnostic Potential:

  • Patient stratification for AR-targeted therapy trials

  • Identification of candidates for TET2-targeting experimental therapies

  • Longitudinal monitoring of expression changes during treatment

Research has established that:

• In mCRPC cohorts, the expression level of ZNF397 significantly correlates with progression-free survival time of patients undergoing AR-targeted therapies

• Multivariate-corrected Cox hazard analysis identified ZNF397 expression and tumor mutation count as the only significant risk factors associated with resistance to AR-targeted therapy

• Patients divided by ZNF397 expression (above or below median) showed significantly different rates of developing therapy resistance

These findings suggest that ZNF397 expression analysis could be incorporated into clinical decision-making to identify patients likely to benefit from AR-targeted therapies versus those who might require alternative approaches targeting epigenetic mechanisms.

What are the challenges and solutions for using ZNF397 antibodies in multiplexed imaging approaches?

As cancer research moves toward more comprehensive spatial profiling of tumor microenvironments, multiplexed detection of ZNF397 presents specific challenges:

For successful multiplexed imaging including ZNF397:

• Panel Design Considerations:

  • Include AR and TET2 for pathway analysis

  • Add lineage markers (luminal, basal, neuroendocrine) to assess plasticity

  • Include proliferation markers (Ki67) for functional correlation

• Technology Selection:

  • Mass cytometry (CyTOF) for suspension cell analysis

  • Multiplex immunofluorescence (m-IF) for tissue architecture preservation

  • Digital spatial profiling (DSP) for regional quantification

• Data Analysis Approaches:

  • Single-cell segmentation with nuclear identification

  • Quantitative intensity measurements normalized to controls

  • Spatial relationship mapping between ZNF397, AR, and other markers

These approaches can reveal heterogeneity in ZNF397 expression within tumors and correlate this with therapy response markers at the single-cell level, providing a more nuanced understanding of resistance mechanisms.

Human research has demonstrated heterogeneity of ZNF397 expression in prostate cancer samples, with depletion observed in 10-25% of patients . This heterogeneity may be critical for understanding mixed therapy responses and developing targeted interventions.

By addressing these methodological challenges, researchers can leverage ZNF397 antibodies to gain deeper insights into the spatial organization of resistance mechanisms in prostate cancer and other malignancies.